Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet-α, protamine). [PDF]
Br J Clin PharmacolBleeding events are common in patients prescribed anticoagulants and can have devastating consequences. Several specific and nonspecific agents have been developed to reverse the effects of anticoagulant drugs or toxins. Vitamin K, as the oldest of these antidotes, specifically counteracts the effects of pharmaceuticals and rodenticides designed to ...
Bekka E, Liakoni E.
europepmc +2 more sources
Use of idarucizumab for emergency surgery in patients taking dabigatran
Атеротромбоз, 2022 This article presents modern possibilities for the provision of emergency surgical care to patients with atrial fibrillation, who administered dabigatran etexilate.
O. M. Nesterova +5 more
doaj +1 more source
How we treat bleeding associated with direct oral anticoagulants [PDF]
, 2016 Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo +4 more
core +1 more source
Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
Research and Practice in Thrombosis and Haemostasis, 2021 Background Idarucizumab, a monoclonal antibody fragment that reverses the anticoagulant effect of dabigatran, was approved for use in Canada in 2016. Objective Our objective was to assess the safety of idarucizumab among patients who received the drug ...
Jameel Abdulrehman +6 more
doaj +1 more source
Frontiers in Medicine, 2020 Background: Idarucizumab has been included in guidelines for the management of bleeding or surgical procedure in dabigatran-treated patients without need for biological monitoring.
Nicolas Gendron +39 more
doaj +1 more source
Future Science OA, 2021 Background: Novel oral anticoagulants are used in atrial fibrillation. Idarucizumab has been approved for reversal of dabigatran in situations of life-threatening hemorrhage or emergency surgery.
Eran Kalmanovich +12 more
doaj +1 more source
Teendők súlyos vérzés vagy sürgős sebészeti beavatkozás esetén direkt orális antikoaguláns gyógyszerrel kezeltekben. Az új dabigatran-antidótum: idarucizumab helye a klinikai gyakorlatban [PDF]
, 2016 Absztrakt Az elmúlt hat évtizedben csak a K-vitamin-antagonista kumarinokat alkalmazhattuk orális antikoagulánsként.
Boda, Zoltán
core +1 more source
Frontiers in Neurology, 2021 Background: Intracranial hemorrhage is a severe and possibly fatal consequence of anticoagulation therapy. Idarucizumab is used in dabigatran-treated patients suffering from intracranial hemorrhage (ICH) to reverse the anticoagulant effect of dabigatran.
Senta Frol +4 more
doaj +1 more source
Activated prothrombin complex in the management of direct thrombin inhibitor-associated intracerebral haemorrhage. [PDF]
, 2006 Intracerebral haematoma expansion independently predicts poor functional outcome and mortality. Therefore, it is important to act quickly to arrest this expansion.
Abeysinghe, C +7 more
core +4 more sources
Dental management of patients taking novel oral anticoagulants (NOAs): dabigatran [PDF]
, 2017 A new group of oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) with clear advantages over classic dicoumarin oral anticoagulants (warfarin and acenocoumarol) has been developed in recent years.
Albaladejo Martínez, Alberto +2 more
core +2 more sources